These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25251804)

  • 1. The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective.
    Saynor ZL; Barker AR; Oades PJ; Williams CA
    Pediatr Phys Ther; 2014; 26(4):454-61. PubMed ID: 25251804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.
    Edgeworth D; Keating D; Ellis M; Button B; Williams E; Clark D; Tierney A; Heritier S; Kotsimbos T; Wilson J
    Clin Sci (Lond); 2017 Aug; 131(15):2037-2045. PubMed ID: 28611235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.
    Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ
    Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
    Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
    Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States.
    Taylor-Cousar J; Niknian M; Gilmartin G; Pilewski JM;
    J Cyst Fibros; 2016 Jan; 15(1):116-22. PubMed ID: 25682022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
    Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
    Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.
    Sawicki GS; Dasenbrook E; Fink AK; Schechter MS
    Ann Am Thorac Soc; 2015 Aug; 12(8):1146-52. PubMed ID: 26073026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
    De Boeck K; Munck A; Walker S; Faro A; Hiatt P; Gilmartin G; Higgins M
    J Cyst Fibros; 2014 Dec; 13(6):674-80. PubMed ID: 25266159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological mechanisms of dyspnea relief following ivacaftor in cystic fibrosis: a case report.
    Quon BS; Schaeffer MR; Molgat-Seon Y; Wilkie SS; Wilcox PG; Guenette JA
    Respir Physiol Neurobiol; 2015 Jan; 205():105-8. PubMed ID: 25447681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
    McKone EF; Borowitz D; Drevinek P; Griese M; Konstan MW; Wainwright C; Ratjen F; Sermet-Gaudelus I; Plant B; Munck A; Jiang Y; Gilmartin G; Davies JC;
    Lancet Respir Med; 2014 Nov; 2(11):902-910. PubMed ID: 25311995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial.
    Quittner A; Suthoff E; Rendas-Baum R; Bayliss MS; Sermet-Gaudelus I; Castiglione B; Vera-Llonch M
    Health Qual Life Outcomes; 2015 Jul; 13():93. PubMed ID: 26135562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation.
    Dilokthornsakul P; Hansen RN; Campbell JD
    Eur Respir J; 2016 Jun; 47(6):1697-705. PubMed ID: 27126691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 19. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
    Seliger VI; Rodman D; Van Goor F; Schmelz A; Mueller P
    J Cyst Fibros; 2013 Dec; 12(6):706-13. PubMed ID: 23628510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.